Table 1.

Effect of Different Treatments on the Kidney Weight/Body Weight Ratio, Blood Urea, Serum Creatinine, Creatinine Clearance, UAER, Urinary NAG and Urinary GGT in the Studied Groups

	Control	Carboplatin	Carboplatin+ Candesartan	Carboplatin + CoQ10	Carboplatin + CMC	Carboplatin + Candesartan+CoQ10	F-value	df
Kidney weight/body weight ratio	6.54±0.2	20.6±0.58a	13.01 ±0.54b	17.39±0.47b	19.37±0.45	9.18±0.15bcd	174.34	51
Blood urea (mg/dl)	19.2 ± 0.54	74.32± 3.13a	41.17±0.66b	49.12±0.91b	71.51±2.16	31.89 ±0.64bcd	193.65	51
Serum creatinine (mg/dl)	0.52 ± 0.01	2.75 ± 0.06a	1.82±0.04b	1.98±0.04b	2.83±0.07	1.32±0.03bcd	107.21	51
Creatinine clearance (ml/min)	1.25 ± 0.04	0.43 ± 0.03a	0.82±0.05b	0.78±0.04b	0.41±0.02	1.06±0.04bcd	81.78	51
Urinary GGT (U/L)	821.34±22.8	2132 ±41.2a	1435.2±31.2b	1489.4±29.7b	2214.2±46.1	1067.6±25.1bcd	121.18	51
Urinary NAG (U/L)	0.22 ± 0.01	1.27 ± 0.04a	0.68±0.03b	0.73±0.03b	1.31±0.05	0.41±0.02bcd	273.80	51
UAER (mg/day)	3.08±0.18	13.17 ±0.53a	6.81 ±0.43b	7.34±0.48b	12.95±0.5	4.23±0.21bcd	94.01	51

^aSignificant compared to the control group (p-value less than 0.05);

^bSignificant compared to carboplatin group (p-value less than 0.05);

^cSignificant compared to carboplatin + candesartan group (p-value less than 0.05);

^dSignificant compared to carboplatin + CoQ10 group (p-value less than 0.05).